Netakimab
CAS No. 1796570-08-5
Netakimab( —— )
Catalog No. M36816 CAS No. 1796570-08-5
Netakimab (BCD 085) is a humanized camel-derived monoclonal antibody targeting interleukin-17A, which can be used to study spondyloarthritis and plaque psoriasis.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 708 | In Stock |
|
| 10MG | 1121 | In Stock |
|
| 25MG | 1691 | In Stock |
|
| 50MG | 2213 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameNetakimab
-
NoteResearch use only, not for human use.
-
Brief DescriptionNetakimab (BCD 085) is a humanized camel-derived monoclonal antibody targeting interleukin-17A, which can be used to study spondyloarthritis and plaque psoriasis.
-
DescriptionNetakimab is an anti-IL-17 monoclonal antibody. Nerelimomab can be used for research of ankylosing spondylitis, psoriatic arthritis, moderate-to-severe plaque psoriasis.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayApoptosis
-
TargetIL Receptor
-
RecptorIL Receptor
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1796570-08-5
-
Formula WeightApproximately 145.74 kDa.
-
Molecular Formula——
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Puig L, et al. Efficacy and Safety of Netakimab, A Novel Anti-IL-17 Monoclonal Antibody, in Patients with Moderate to Severe Plaque Psoriasis. Results of A 54-Week Randomized Double-Blind Placebo-Controlled PLANETA Clinical Trial. Dermatol Ther (Heidelb). 2021 Aug;11(4):1319-1332. ?
molnova catalog
related products
-
Enokizumab
Enokizumab?(MEDI-528) is a monoclonal antibody against interleukin IL-9. Enokizumab can be used to study asthma.
-
IL-17A inhibitor 1
IL-17A inhibitor 1 (example 24) is an inhibitor of IL-17A.
-
Ayanin
Ayanin has vasorelaxant activity, it also may have the potential for use in treating allergic asthma. The IC50 value of Ayanin is 2.2microM for inhibiting interleukin IL-4 production from purified basophils. Ayanin is a non-selective phosphodiesterase1-4 inhibitor and can be used for respiratory disease researches.
Cart
sales@molnova.com